A clinical phase-I/II study with glioblastoma patients in Brazil investigated the natural compound perillyl alcohol for intranasal delivery as an aerosol. The results were encouraging and, as of 2016, a similar trial has been initiated in the United States. Cannabinoids
The efficacy of cannabinoids (cannabis derivatives) is known in oncology (through capsules of tetrahydrocannabinol (THC) or the synthetic analogue nabilone), on the one hand to combat nausea and vomiting induced by chemotherapy, on the other to stimulate appetite and lessen the sense of anguish or the actual pain. Their ability to inhibit growth and angiogenesis in malignant gliomas in mouse models has been demonstrated. The results of a pilot study on the use of THC in end-stage patients with recurrent glioblastoma appeared worthy of further study. A potential avenue for future research rests on the discovery that cannabinoids are able to attack the neoplastic stem cells of glioblastoma in mouse models, with the result on the one hand of inducing their differentiation into more mature, possibly more "treatable" cells, and on the other hand to inhibit tumorigenesis. See also
Adegramotide
List of people with brain tumors

References
External links

Information about Glioblastoma Multiforme (GBM) from the American Brain Tumor Association
AFIP Course Syllabus – Astrocytoma WHO Grading Lecture Handout
The Beijing-3 strain was the main variant of the vaccine used in the Peoples Republic of China from 1968 until 2005.Three second-generation vaccines have entered markets since then: SA14-14-2, IC51 and ChimeriVax-JE. The live-attenuated SA14-14-2 strain was introduced in China in 1988. It is much cheaper than alternative vaccines, and is administered to 20 million Chinese children each year.A purified, formalin-inactivated, wholevirus vaccine known as IC51 (marketed in Australia and New Zealand as JESPECT and elsewhere as IXIARO) was licensed for use in the United States, Australia, and Europe during the spring of 2009. It is based on a SA14-14-2 strain and cultivated in Vero cells. In September 2012, the Indian firm Biological E. Limited launched an inactivated cell culture derived vaccine based on SA 14-14-2 strain which was developed in a technology transfer agreement with Intercell and is a thiomersal-free vaccine.Another vaccine, a live-attenuated recombinant chimeric virus vaccine developed using the Yellow fever virus known as ChimeriVax-JE (marketed as IMOJEV) was licensed for use in Australia in August 2010 and in Thailand in December 2012. References
External links
"Japanese Encephalitis Vaccine". Drug Information Portal. U.S. National Library of Medicine.